| Autor: |
Plan Sangnier A; Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.; Laboratoire Matière et Systèmes Complexes, CNRS and University Paris Diderot, Paris, France., Aufaure R; Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France., Motte L; Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France., Wilhelm C; Laboratoire Matière et Systèmes Complexes, CNRS and University Paris Diderot, Paris, France., Guenin E; Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.; Sorbonne Universités, Université de Technologie de Compiègne, Integrated Transformations of Renewable Matter Laboratory (EA TIMR 4297 UTC-ESCOM), Compiègne, France., Lalatonne Y; Inserm U1148, LVTS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France.; Service de Médecine Nucléaire, Hôpital Avicenne Assistance Publique-Hôpitaux de Paris, Bobigny, France. |
| Abstrakt: |
A gold therapeutic nanoplatform with the same molecule used as reductant, coating and therapeutic agent has been developed in a one-pot, one-phase process using alendronate, a drug from the bisphosphonate family known for its antitumor effects. In addition, the core made of gold nanoparticles (NPs) brings thermal functionalities under irradiation within the first biological window (650-900 nm). The Au@alendronate nanoplatform thus provided a combined antitumor activity through drug delivery and photothermal therapy. Au@alendronate NPs inhibited in vitro the proliferation of prostate cancer cells (PC3) in a dose-dependent manner, with an IC 50 value of 100 µM. Under NIR irradiation a temperature increase was observed leading to a reduction of the IC 50 value to 1 µM, with total tumor cell death at 100 µM. |
